Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. (Q35129531)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

4

Camelia S Sima

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Samantha L Kass

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Kaitlin Woo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Michelle S Ginsberg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Lee M Krug

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

14 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

271-274

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.

12 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4343315

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4343315

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4343315

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4343315

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4343315

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4343315

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4343315

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4343315

A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4343315

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4343315

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4343315

Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24690410

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24690410

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.LUNGCAN.2014.03.006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24690410%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference